Categoría: Spinal Cord Injury

Doctors, scientists, and now also institutional investors lack confidence in Geron’s highly publicized upcoming clinical trial with human embryonic stem cells.

A young boy who was treated with fetal stem cell therapy developed a life-threatening tumor which was directly traced to the fetal stem cells that he received.

The company Neuralstem has been awarded a patent for its proprietary technology to immortalize human neural stem cells.

The stem cell company Neuralstem has filed an application with the FDA to begin the first clinical trials ever to be conducted with adult stem cells in the treatment of amyotrophic lateral sclerosis.

Scientists at the Salk Institute have demonstrated with human stem cells that an antioxidant commonly found in plants can improve amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

The stem cell company Neuralstem, Inc., announces the licensing of patents for the delivery of targeted spinal cord therapeutics.

With newer, improved techniques for the administration of adult stem cells, an already viable therapy is made even more effective in the treatment of devastating spinal cord injuries.

Plans for the first clinical trial in the U.S. ever to be conducted with embryonic stem cells have now been postponed by the FDA.

As the first clinical trials ever to be conducted in the U.S. with embryonic stem cells are about to commence, FDA regulators convene a special meeting to debate the inherent risks and dangers.

A new trial using adult stem cells to treat spinal cord injury will be conducted in Australia.